title: First report of a vincristine dose-related Raynaud's phenomenon in an adolescent with malignant brain tumor.
abstract: The authors report a case of a vincristine-induced, reproducible dose-related Raynaud's phenomenon. It occurred in a 14-year-old boy with a malignant brain tumor who received repeated vincristine injections. The authors describe how they handled this severe secondary Raynaud's phenomenon with acral cutaneous tissue necrosis. Reducing the dose of the vinca-alkaloid injections, together with an additional medication with a calcium-channel blocking agent, was a successful strategy in this patient. There are few case reports of secondary Raynaud's phenomenon in adult oncologic patients receiving certain anticancer drugs (including vincristine, bleomycin, and cisplatin), and to the authors' knowledge this kind of vincristine toxicity has not previously been described in either adults or children.
authors.affiliation: Department of Pediatric Hematology and Oncology, University Children's Hospital, Homburg/Saar, Germany. kisgot@uniklinik-saarland.de
authors.forename: Sven
authors.initials: S
authors.lastname: Gottschling
authors.forename: Sascha
authors.initials: S
authors.lastname: Meyer
authors.forename: Harald
authors.initials: H
authors.lastname: Reinhard
authors.forename: Thomas
authors.initials: T
authors.lastname: Krenn
authors.forename: Norbert
authors.initials: N
authors.lastname: Graf
mesh_terms: D000293:Adolescent; D001932:Brain Neoplasms / Q000150:complications* / Q000188:drug therapy; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D006801:Humans; D008297:Male; D011928:Raynaud Disease / Q000139:chemically induced*; D014750:Vincristine / Q000009:adverse effects* / Q000627:therapeutic use
chemical_list: D002121:Calcium Channel Blockers; D014750:Vincristine